Compare STRO & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRO | VYGR |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | United States | United States |
| Employees | 131 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 338.9M | 194.0M |
| IPO Year | N/A | 2015 |
| Metric | STRO | VYGR |
|---|---|---|
| Price | $25.06 | $3.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 3 |
| Target Price | ★ $26.38 | $21.00 |
| AVG Volume (30 Days) | 168.4K | ★ 873.3K |
| Earning Date | 03-23-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,135,000.00 |
| Revenue This Year | N/A | $33.19 |
| Revenue Next Year | $13.45 | $14.68 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.52 | $2.65 |
| 52 Week High | $27.96 | $5.55 |
| Indicator | STRO | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 63.16 | 44.29 |
| Support Level | $0.76 | $3.72 |
| Resistance Level | $27.96 | $4.43 |
| Average True Range (ATR) | 2.15 | 0.27 |
| MACD | -0.08 | -0.04 |
| Stochastic Oscillator | 78.98 | 10.18 |
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.